

Remarks

Claims 1, 2, 10, 11, 16, 28-30, 37-41, 46 and 56-61 were pending in the instant application. Claims 1, 2, 28-30 and 37, 38, 40, 46 and 56-61 have been canceled without prejudice; claims 39 and 41 have been withdrawn and amended; claims 10, 11 and 16 have been amended; and new claims 89-91 have been added. Support for these amendments and newly added claims can be found throughout the specification and the claims as originally filed, for example, at least in original claims 13, 19 and 28-30; in the Examples starting at page 48; and in Figures 1 and 2. *No new matter has been added.*

Upon entry of the amendment, claims 10, 11, 16, 39, 41 and 89-91 will be pending in the instant application.

Amendments to and/or cancellation of claims should in no way be construed as an acquiescence to any of the Examiner's objections and/or rejections. The amendments to and/or cancellation of claims are being made solely to expedite prosecution of the above-identified application. Applicants reserve the option to further prosecute the same or similar claims in the present or another patent application. The amendments made to the claims are not related to any issues of patentability.

Response to Restriction Requirement

The Examiner has required restriction between the following inventions in the above-identified application:

Group I: claims 1, 2, 10, 11, 16, 28-30 and 46 drawn to a method of detecting abnormal cell growth and determining a stage of abnormal cell growth comprising the assessment of Pin 1 levels in a sample, wherein the Pin 1 levels are drawn solely to protein, classified in class 435, subclass 7.1, for example.

Group II: claims 1, 10, 28 and 9 drawn to a method of detecting abnormal cell growth and determining a stage of abnormal cell growth comprising the assessment of Pin 1 levels in a sample, wherein the Pin 1 levels are drawn solely to nucleic acid levels, classified in class 435, subclass 6, for example.

Group III: claims 37 and 38, drawn to a method of evaluating the efficacy of treatment of abnormal cell growth comprising the levels of Pin 1 in at least two test samples, wherein a decrease in the Pin 1 levels as compared to controls is indicative of effective treatment, wherein

the Pin 1 levels are drawn solely to Pin 1 protein levels, classified in class 435, subclass 7.21, for example.

Group IV: claim 37 drawn in part to a method of evaluating the efficacy of treatment of abnormal cell growth comprising comparing the levels of Pin 1 in at least two samples, wherein a decrease in the Pin 1 levels as compared to controls is indicative of effective treatment, wherein the Pin 1 levels are drawn solely to nucleic acid levels, classified in class 435, subclass 5, for example.

Group V: claims 39-41, drawn in part to a kit comprising one or more reagents for detecting Pin 1 protein levels, classified in class 530, subclass 387.1, for example.

Group VI: claims 39-41, drawn in part to a kit comprising one or more reagents for detecting Pin 1 protein levels, classified in class 536, subclass 24.31, for example.

Group VII: claims 56-61, drawn in part to a method of treating a subject comprising the administration of a Pin 1 modulator, wherein the modulator specifically modulates the protein, classified in class 424, subclass 130.1, for example.

Group VIII: claims 56-61, drawn in part to a method of treating a subject comprising the administration of a Pin 1 modulator, wherein the modulator specifically modulates the nucleic acid, classified in class 514, subclass 44, for example.

Applicants hereby elect *Group I* for continued examination.


Applicants reserve the right to traverse the restriction between the aforementioned groups in this or a continuing application. Applicants further reserve the right to pursue the non-elected groups in one or more divisional applications. The Examiner has required restriction between product and process claims. Applicants understand that where claims directed to a product are allowed, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with MPEP §821.04.

Conclusion

It is respectfully submitted that this application is in condition for allowance. If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned attorney at (617) 227-7400.

Dated: July 5, 2006

Respectfully submitted,

By 

Cynthia L. Kanik, Ph.D.

Registration No.: 37,320

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant